Literature DB >> 15871504

Is gross-total resection sufficient treatment for posterior fossa ependymomas?

Leland Rogers1, Jeanette Pueschel, Robert Spetzler, William Shapiro, Stephen Coons, Terry Thomas, Burton Speiser.   

Abstract

OBJECT: The goals of this study were to analyze outcomes in patients with posterior fossa ependymomas, determine whether gross-total resection (GTR) alone is appropriate treatment, and evaluate the role of radiation therapy.
METHODS: All patients with newly diagnosed intracranial ependymomas treated at Barrow Neurological Institute between 1983 and 2002 were identified. Those with supratentorial primary lesions, subependymomas, or neuraxis dissemination were excluded. Forty-five patients met the criteria for the study. Gross-total resection was accomplished in 32 patients (71%) and subtotal resection (STR) in 13 (29%). Radiation therapy was given to 25 patients: 13 following GTR and 12 after STR. The radiation fields were craniospinal followed by a posterior fossa boost in six patients and posterior fossa or local only in the remaining patients. With a median follow-up period of 66 months, the median duration of local control was 73.5 months with GTR alone, but has not yet been reached for patients with both GTR and radiotherapy (p = 0.020). The median duration of local control following STR and radiotherapy was 79.6 months. The 10-year actuarial local control rate was 100% for patients who underwent GTR and radiotherapy, 50% for those who underwent GTR alone, and 36% for those who underwent both STR and radiotherapy, representing significant differences between the GTR-plus-radiotherapy and GTR-alone cohorts (p = 0.018), and between the GTR-plus-radiotherapy and the STR-plus-radiotherapy group (p = 0.003). There was no significant difference in the 10-year actuarial local control rate between the GTR-alone and STR-plus-radiotherapy cohorts (p = 0.370). The 10-year overall survival was numerically superior in patients who underwent both GTR and radiotherapy: 83% compared with 67% in those who underwent GTR alone and 43% in those who underwent both STR and radiotherapy. These differences did not achieve statistical significance. Univariate analyses revealed that radiotherapy, tumor grade, and extent of resection were significant predictors of local control.
CONCLUSIONS: Gross-total resection should be the intent of surgery when it can be accomplished with an acceptable degree of morbidity. Even after GTR has been confirmed with postoperative imaging, however, adjuvant radiotherapy significantly improves local control. The authors currently recommend the use of postoperative radiotherapy, regardless of whether the resection is gross total or subtotal.

Entities:  

Mesh:

Year:  2005        PMID: 15871504     DOI: 10.3171/jns.2005.102.4.0629

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  34 in total

1.  Post-operative radiation improves survival in children younger than 3 years with intracranial ependymoma.

Authors:  Matthew Koshy; Shayna Rich; Thomas E Merchant; Usama Mahmood; William F Regine; Young Kwok
Journal:  J Neurooncol       Date:  2011-06-03       Impact factor: 4.130

2.  Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.

Authors:  Elizabeth Vera-Bolanos; Kenneth Aldape; Ying Yuan; Jimin Wu; Khalida Wani; Mary Jo Necesito-Reyes; Howard Colman; Girish Dhall; Frank S Lieberman; Philippe Metellus; Tom Mikkelsen; Antonio Omuro; Sonia Partap; Michael Prados; H Ian Robins; Riccardo Soffietti; Jing Wu; Mark R Gilbert; Terri S Armstrong
Journal:  Neuro Oncol       Date:  2014-08-13       Impact factor: 12.300

3.  Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients.

Authors:  Philippe Metellus; Jacques Guyotat; Olivier Chinot; Anne Durand; Marylin Barrie; Roch Giorgi; Anne Jouvet; Dominique Figarella-Branger
Journal:  Neuro Oncol       Date:  2010-05-19       Impact factor: 12.300

4.  Is H3K27me3 status really a strong prognostic indicator for pediatric posterior fossa ependymomas? A single surgeon, single center experience.

Authors:  Bahattin Tanrıkulu; Ayça Erşen Danyeli; M Memet Özek
Journal:  Childs Nerv Syst       Date:  2020-02-05       Impact factor: 1.475

5.  Outcome of postoperative radiation therapy for pediatric intracranial ependymoma: a single-institution review.

Authors:  Rawee Ruangkanchanasetr; Thiti Swangsilpa; Putipun Puataweepong; Mantana Dhanachai; Ake Hansasuta; Atthaporn Boongird; Nongnuch Sirachainan; Suradej Hongeng
Journal:  Childs Nerv Syst       Date:  2019-06-16       Impact factor: 1.475

Review 6.  Initial management of childhood brain tumors: neurosurgical considerations.

Authors:  Farideh Nejat; Mostafa El Khashab; James T Rutka
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

Review 7.  Brain tumors across the age spectrum: biology, therapy, and late effects.

Authors:  Thomas E Merchant; Ian F Pollack; Jay S Loeffler
Journal:  Semin Radiat Oncol       Date:  2010-01       Impact factor: 5.934

8.  Supratentorial ependymoma: disease control, complications, and functional outcomes after irradiation.

Authors:  Efrat Landau; Frederick A Boop; Heather M Conklin; Shengjie Wu; Xiaoping Xiong; Thomas E Merchant
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-12-11       Impact factor: 7.038

Review 9.  Survival following treatment for intracranial ependymoma: a review.

Authors:  G Tamburrini; M D'Ercole; B L Pettorini; M Caldarelli; L Massimi; C Di Rocco
Journal:  Childs Nerv Syst       Date:  2009-04-22       Impact factor: 1.475

10.  A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.

Authors:  Mark R Gilbert; Ying Yuan; Jimin Wu; Tito Mendoza; Elizabeth Vera; Antonio Omuro; Frank Lieberman; H Ian Robins; Elizabeth R Gerstner; Jing Wu; Patrick Y Wen; Tom Mikkelsen; Kenneth Aldape; Terri S Armstrong
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.